Author:
Canver Matthew C.,Satlin Michael J.,Westblade Lars F.,Kreiswirth Barry N.,Chen Liang,Robertson Amy,Fauntleroy Kathy,La Spina Marisa,Callan Katrina,Jenkins Stephen G.
Abstract
ABSTRACT
Carbapenem-resistant Enterobacteriaceae (CRE) strains are an urgent public health threat. We evaluated the in vitro activities of 19 antimicrobial agents, including imipenem-relebactam, against (i) 106 CRE bloodstream isolates that primarily expressed Klebsiella pneumoniae carbapenemase (KPC) and (ii) 20 OXA-48-like-expressing CRE isolates. Ninety-five percent of CRE bloodstream isolates were susceptible to imipenem-relebactam. In contrast to their comparable activities against KPC-producing CRE strains, ceftazidime-avibactam was more active in vitro against OXA-48-like CRE strains than was imipenem-relebactam (90% susceptible versus 15% susceptible).
Funder
Merck (Merck & Co., Inc.)
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference10 articles.
1. 1. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA. https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.
2. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies;Satlin;Clin Infect Dis,2014
3. OXA-48-like carbapenemases producing Enterobacteriaceae in different niches;Mairi;Eur J Clin Microbiol Infect Dis,2018
4. Carbapenemase-producing organisms: a global scourge;Bonomo;Clin Infect Dis,2018
5. New β-lactamase inhibitors: a therapeutic renaissance in an MDR world;Drawz;Antimicrob Agents Chemother,2014
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献